What type of study is this?

Pediatric Intravenous Iron Therapy: Evaluating the Safety and Efficacy of Iron Isomaltoside and Low‐Molecular‐Weight Dextran

View Full Paper

Ask AI

Bookmark

Authors

Retrospective cohort study reports safety and efficacy of intravenous iron formulations in children, indicating both options are viable treatments.

Both iron isomaltoside and low-molecular-weight dextran effectively treat iron deficiency in children, showing significant hematological responses.
Participants experienced a mean increase in hemoglobin of 32.4 g/L for iron isomaltoside and 33.1 g/L for low-molecular-weight dextran, with no significant differences.
The study included 72 pediatric patients, assessing responses with metrics like reticulocyte hemoglobin equivalent and ferritin levels.
Safety was upheld, as adverse events were mild and comparable between both iron formulations, suggesting both treatments are safe.

Dragūnė et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

View Full Paper

Ask AI

Bookmark

Authors

Retrospective cohort study reports safety and efficacy of intravenous iron formulations in children, indicating both options are viable treatments.

Both iron isomaltoside and low-molecular-weight dextran effectively treat iron deficiency in children, showing significant hematological responses.
Participants experienced a mean increase in hemoglobin of 32.4 g/L for iron isomaltoside and 33.1 g/L for low-molecular-weight dextran, with no significant differences.
The study included 72 pediatric patients, assessing responses with metrics like reticulocyte hemoglobin equivalent and ferritin levels.
Safety was upheld, as adverse events were mild and comparable between both iron formulations, suggesting both treatments are safe.

Dragūnė et al. (2025) studied this question.

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark